Van Herwaarden MA et al. |
The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10759625
|
Ramirez B and Richter JE |
Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. |
1993 |
Aliment. Pharmacol. Ther. |
pmid:8094981
|
Catnach SM et al. |
Dose-dependent stimulation of gallbladder contraction by intravenous erythromycin in man. |
1993 |
Aliment. Pharmacol. Ther. |
pmid:8439638
|
Russo A et al. |
Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15274670
|
Haans JJ and Masclee AA |
Review article: The diagnosis and management of gastroparesis. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:18081647
|
Bai Y et al. |
Meta-analysis: erythromycin before endoscopy for acute upper gastrointestinal bleeding. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21615438
|
Netzer P et al. |
Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12182748
|
Athanasakis E et al. |
Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12182757
|
Chen CL et al. |
Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929393
|
Annese V et al. |
Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218089
|
Chiba T et al. |
Motilides accelerate regional gastrointestinal transit in the dog. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886053
|
Landry C et al. |
Could oral erythromycin optimize high energy continuous enteral nutrition? |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971296
|
Ehrenpreis ED et al. |
Which form of erythromycin should be used to treat gastroparesis? A pharmacokinetic analysis. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9690728
|
Jameson JS et al. |
Oral or intravenous erythromycin has no effect on human distal colonic motility. |
1992 |
Aliment. Pharmacol. Ther. |
pmid:1420750
|
Medhus AW et al. |
Low-dose intravenous erythromycin: effects on postprandial and fasting motility of the small bowel. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10651665
|
Curry JI et al. |
Review article: erythromycin as a prokinetic agent in infants and children. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11328252
|
Boecxstaens V et al. |
Modulation of the postprandial acid and bile pockets at the gastro-oesophageal junction by drugs that affect gastric motility. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21517922
|
Laine L et al. |
Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791949
|
Wehrmann T et al. |
Effect of erythromycin on human biliary motility. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791972
|
Mosonyi L et al. |
[Infectious and neoplastic complications in rheumatoid arthritis]. |
1974-1975 |
Allerg Immunol (Leipz) |
pmid:4282826
|